目的 8-羟基鸟嘌呤核苷酸酶(8-oxoguanine nucleoside triphosphatase,MTH1)作为一种DNA氧化损伤修复酶,在肿瘤发生及发展过程中发挥重要作用,有望成为抗肿瘤治疗的新靶点,但是目前关于MTH1与临床病理学之间的关联研究较少。本研究旨在分析MTH1在晚期胃癌组织中的表达情况,并探讨MTH1的表达情况与临床病理特征及预后的关系。方法回顾性分析2008-01-01-2013-01-01天津医科大学肿瘤医院经病理确诊的125例晚期胃癌患者临床及随访资料,并采用免疫组织化学方法检测MTH1在胃癌组织中的表达情况。分析MTH1表达与临床病理学及生存预后之间的关系。结果胃癌组织和正常组织中MTH1阳性表达率分别为52%和20%,差异有统计学意义,χ2=7.079,P=0.008。MTH1表达状态与患者年龄、性别、肿瘤大小、肿瘤分化程度及肿瘤部位无关。MTH1阳性表达组和阴性组中位PFS分别为4.83和6.27个月,差异有统计学意义,χ2=5.973,P=0.019。MTH1阴性表达组中位OS为13.53个月,明显高于MTH1阳性表达组的8.27个月,χ2=11.794,P=0.001。多因素分析结果显示,MTH1表达状态、肿瘤组织学类型、肿瘤部位和化疗前CEA水平为晚期胃癌独立预后因素。MTH1阳性表达组DCR为56%,而MTH1阴性表达组DCR为73%,χ2=4.363,P=0.037。结论 MTH1的表达状态与晚期胃癌患者预后相关,对判断晚期胃癌患者生存预后有一定的提示意义。 Objective 8-oxoguanine nucleoside triphosphatase (MTH1), as a DNA oxidative damage repair enzyme, plays an important role in tumorigenesis and development and is expected to become a new target of anti-tumor therapy. However, At present there is little research on the relationship between MTH1 and clinicopathology. The purpose of this study was to analyze the expression of MTH1 in advanced gastric cancer and to investigate the relationship between the expression of MTH1 and clinicopathological features and prognosis. Methods The clinical and follow - up data of 125 patients with advanced gastric cancer confirmed by pathology at Tumor Hospital of Tianjin Medical University from January 1, 2008 to January 31, 2008 were retrospectively analyzed. The expression of MTH1 in gastric cancer tissues was detected by immunohistochemistry. To analyze the relationship between MTH1 expression and clinical pathology and survival and prognosis. Results The positive rates of MTH1 in gastric cancer tissues and normal tissues were 52% and 20%, respectively, with statistical significance (χ2 = 7.079, P = 0.008). MTH1 expression status and age, gender, tumor size, tumor differentiation and tumor site has nothing to do. The median PFS of MTH1 positive group and negative group were 4.83 and 6.27 months respectively, the difference was statistically significant (χ2 = 5.973, P = 0.019). The median OS was 13.53 months in MTH1-negative group, which was significantly higher than that in MTH1-positive group (8.27 months, χ2 = 11.794, P = 0.001). Multivariate analysis showed that the expression of MTH1, tumor histological type, tumor location and CEA level before chemotherapy were independent prognostic factors for advanced gastric cancer. The DCR of MTH1 positive group was 56%, while that of MTH1 negative group was 73%, χ2 = 4.363, P = 0.037. Conclusions The expression of MTH1 is correlated with the prognosis of patients with advanced gastric cancer and may be helpful in judging the prognosis of patients with advanced gastric cancer.